GlassScriptPhysician profile
Malorie Deanne Evans
NPI 1841672854
$4,313.40
in general payments reported to CMS, 2019-2025
23 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.15 · 2022: $103 · 2023: $614 · 2024: $1,825 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,184.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $619.82 | 2021-2025 | Wainua, Farxiga |
| United Therapeutics Corporation | $514.00 | 2023-2025 | Tyvaso, Remodulin, Orenitram |
| Novartis Pharmaceuticals Corporation | $422.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $399.08 | 2024-2025 | Winrevair |
| Alnylam Pharmaceuticals INC. | $345.68 | 2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $344.87 | 2024-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $317.92 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| E.R. Squibb & Sons, L.L.C. | $201.53 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.52 | 2023-2025 | Jardiance |
| Pfizer INC. | $132.95 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $117.59 | 2023-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $107.15 | 2023-2024 | Xarelto |
| Scpharmaceuticals INC. | $88.99 | 2023-2024 | |
| Bridgebio Pharma, INC. | $88.00 | 2025 | Attruby |
| Abbott Laboratories | $67.69 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $64.10 | 2023 | Inpefa |
| Novo Nordisk INC | $63.24 | 2023-2025 | Wegovy, Ozempic |
| Impulse Dynamics (USA) INC. | $55.03 | 2023-2024 | Optimizer, Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $45.42 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $43.91 | 2023-2024 | |
| Endotronix, INC. | $29.20 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Celgene Corporation | $25.44 | 2024 | Camzyos |
| Biosense Webster, INC. | $19.81 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malorie Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.